Login to Your Account

Analysts Weigh EMDAC Vote on Late-Stage Obesity Drugs

By Jennifer Boggs
Managing Editor

Monday, April 2, 2012

As the dust settled after the two-day Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting ended with a 17-6 vote in favor of requiring large cardiovascular outcomes trials (CVOTs) for all obesity drugs, regardless of cardiovascular risk or signal, analysts began scrambling to gauge whether the recommendations will affect the upcoming FDA decisions for Vivus Inc.'s Qnexa and Arena Pharmaceuticals Inc.'s Lorqess (lorcaserin).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription